Scientists from Memorial Sloan-Kettering Cancer Center and Eureka Therapeutics have collaborated to create a unique monoclonal antibody that can effectively reach inside a cancer cell. The paper, published today in Science Translational Medicine, describes this new approach for attacking WT1, an important intracellular cancer target.

Read the press release

Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Not readable? Change text.